Determinants of Warfarin Metabolism

Recruiting now · Not applicable

Conditions studied: Healthy

In brief

The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin. The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.

Key facts

Study ID

NCT00162474

Run by

Hadassah Medical Organization

People needed

1000

Starts

2003-09-01

Expected to finish

2030-12-01

Last updated by the study team

2026-04-21

Who can join

Age: 20 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age range of 20-50 years old
• The absence of significant disease states

You may not qualify if…

• Known hypersensitivity to warfarin or phenytoin
• Known hepersensitivity to penicillins or cephalosporins (Dicloxacillin part)
• The presence of significant disease states
• Regular use of drugs (including birth control pills)

Where it is running

• Hadassah Medical Organization — Jerusalem, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.